Mineralys Therapeutics Announces Results of 2026 Annual Meeting of Stockholders

On May 21, 2026, Mineralys Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders. During the meeting, stockholders voted on two key proposals. First, three Class III directors—Srinivas Akkaraju, M.D., Ph.D., Brian Taylor Slingsby, M.D., Ph.D., M.P.H., and Daphne Karydas—were elected to serve three-year terms expiring at the 2029 annual meeting. Second, the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified. Both proposals were approved, receiving the necessary affirmative votes from the holders of the company's common stock. No other significant corporate developments or clinical updates were disclosed in this filing.